Key Points
- Director John Schmid sold 20,645 shares on March 30 at an average price of $56.11 for proceeds of about $1.16 million, leaving him with 31,622 shares (a 39.5% reduction in his position).
- The company’s Board announced a share buyback program on March 27; the article reports implausible figures (e.g., "$100,000.00 billion" and "5,352,316.2%"), indicating a likely reporting/formatting error in the release.
- AnaptysBio recently reported a stronger-than-expected quarter (EPS $1.58 and $108.3M revenue vs. estimates of $0.89 and $87.1M) and currently holds a consensus analyst rating of "Moderate Buy" with an average target of $80.10.
AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) Director John Schmid sold 20,645 shares of the company's stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the transaction, the director owned 31,622 shares of the company's stock, valued at approximately $1,774,310.42. This trade represents a 39.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
AnaptysBio Trading Up 1.7%
ANAB stock opened at $57.68 on Friday. AnaptysBio, Inc. has a 12-month low of $15.40 and a 12-month high of $68.39. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -110.92 and a beta of 0.40. The business's 50-day moving average is $56.08 and its 200 day moving average is $44.42.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The company had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. As a group, equities analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.
AnaptysBio announced that its Board of Directors has initiated a share buyback program on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's board of directors believes its stock is undervalued.
Hedge Funds Weigh In On AnaptysBio
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in shares of AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company's stock worth $74,855,000 after acquiring an additional 67,048 shares during the last quarter. State Street Corp raised its holdings in shares of AnaptysBio by 20.6% during the 4th quarter. State Street Corp now owns 1,053,474 shares of the biotechnology company's stock worth $51,072,000 after acquiring an additional 180,042 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company's stock valued at $25,719,000 after acquiring an additional 822,975 shares during the last quarter. 683 Capital Management LLC boosted its position in shares of AnaptysBio by 18.5% during the 4th quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company's stock valued at $31,420,000 after acquiring an additional 101,093 shares during the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of AnaptysBio in the fourth quarter valued at about $21,559,000.
Analyst Ratings Changes
A number of brokerages have weighed in on ANAB. Truist Financial upgraded AnaptysBio to a "hold" rating in a report on Wednesday, March 25th. Barclays upped their target price on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an "overweight" rating in a report on Wednesday, March 4th. Guggenheim reiterated a "buy" rating on shares of AnaptysBio in a research report on Thursday, December 18th. Stifel Nicolaus boosted their price target on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a "buy" rating in a research report on Thursday, March 5th. Finally, UBS Group upped their price objective on shares of AnaptysBio from $70.00 to $90.00 and gave the company a "buy" rating in a research note on Tuesday, March 17th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $80.10.
Check Out Our Latest Report on AnaptysBio
AnaptysBio Company Profile
(
Get Free Report)
AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.
The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
